| | | EXHIBIT 99.01 |
| | Hampshire International Business Park
Chineham Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com |  |
| | | |
| | | |
| | Press Release | |
| | | |
STOCK EXCHANGE ANNOUNCEMENT
23 November 2005
Shire Pharmaceuticals Group plc (the "Company")
The Company announces that it was notified on 22 November 2005 under Sections 198 to 203 of the Companies Act that, at close of business on 17 November 2005, The Goldman Sachs Group, Inc., was interested in 27,000,376 ordinary shares of £0.05p each in the capital of the Company. This holding represents 5.452 per cent of the issued ordinary share capital of the Company.
T MayCompany Secretary
For further information please contact:
| Investor Relations | | Cléa Rosenfeld (Rest of the World) | + | 44 1256 894 160 |
| | | Brian Piper (North America) | + | 1 484 595 8252 |
Notes to editors
Shire Pharmaceuticals Group plc
Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), general products and human genetic therapies. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
For further information on Shire, please visit the Company’s website:www.shire.com.
